


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof



(I)

wherein

$R^1$  and  $R^2$  independently represent H or C1 to 6 alkyl; said alkyl being optionally further substituted by an aryl ring or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said aromatic ring being optionally further substituted by halogen,  $CF_3$ , C1 to 4 alkyl or C1 to 4 alkoxy;

Each  $R^3$  and each  $R^4$  independently represents H or C1 to 6 alkyl; said alkyl being optionally further substituted by OH, C1 to 4 alkoxy, C1 to 4 alkylthio, amino, N-alkylamino or N,N-dialkylamino;

or  $R^3$  and  $R^4$  are bonded together so as to form a 3 to 7 membered ring; said ring optionally incorporating one heteroatom selected from O, S(O)<sub>q</sub> and N;

m represents an integer 1, 2 or 3;

X represents a group S(O), S(O)<sub>2</sub> or C(=O);

$R^5$  represents H or C1 to 6 alkyl; said alkyl being optionally further substituted by halogen, OH or C1 to 6 alkoxy;

Y represents a direct bond;

or Y and  $R^5$  are bonded together such that the group  $-NR^5Y-$  together represents a 4 to 7 membered saturated or partially unsaturated azacyclic ring; said azacyclic ring optionally incorporating one further heteroatom selected from O, S(O)<sub>n</sub> and N; said azacyclic ring being optionally benzo fused; said azacyclic ring being optionally substituted by C1 to 6 alkyl, C1 to 6 alkoxy or OH;

L represents a direct bond;

or L represents O, S(O)<sub>p</sub>, C(O),  $NR^6$ ,  $C(O)NR^6$ ,  $NR^6C(O)$ , ~~divalent C2 to 6 alkynyl~~ alkynylene, ~~divalent C2 to 6 alkenyl~~ alkenylene, ~~divalent C1 to 6 alkyl~~ alkylene, ~~divalent C1 to 6 heteroalkyl~~

heteroalkylene or ~~divalent~~ C3 to 6 ~~heteroalkynyl~~ heteroalkynylene; said ~~divalent-alkyl~~ alkylene, ~~divalent-alkenyl~~ alkenylene or ~~divalent-alkynyl~~ alkynylene group being optionally further substituted by halogen, OH or C1 to 6 alkoxy;

n, p and q independently represent an integer 0, 1 or 2;

G<sup>1</sup> is a monocyclic ring structure of up to 7 ring atoms, which is selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical; or

G<sup>1</sup> is a bicyclic ring structure, wherein each ring in the bicyclic ring structure is, independently, a ring of up to 7 ring atoms, wherein each ring in the bicyclic ring structure is, independently, selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; wherein each ring in the bicyclic ring structure is, independently, optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl,

C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical; or

G<sup>1</sup> is a tricyclic ring structure, wherein each ring in the tricyclic ring structure is, independently, a ring of up to 7 ring atoms, wherein each ring in the tricyclic ring structure is, independently, selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; wherein each ring in the tricyclic ring structure is, independently, optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical; or

G<sup>1</sup> is a tetracyclic ring structure, wherein each ring in the tetracyclic ring structure is, independently, a ring of up to 7 ring atoms, wherein each ring in the tetracyclic ring structure is, independently, selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; wherein each ring in the tetracyclic ring structure is, independently, optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical;

and when G<sup>1</sup> is a bicyclic ring structure, a tricyclic ring structure, or a tetracyclic ring structure, each ring in the bicyclic, tricyclic, or tetracyclic ring structure is, independently, joined to the next ring in the bicyclic, tricyclic, or tetracyclic ring structure by a direct bond, by -O-, by ~~divalent~~ C1 to 6 ~~alkyl~~ alkylene, by ~~divalent~~ C1-6 ~~haloalkyl~~ haloalkylene, by ~~divalent~~ C1 to 6 ~~heteroalkyl~~ heteroalkylene, by ~~divalent~~ C2 to 6 ~~alkenyl~~ alkenylene, by ~~divalent~~ C2 to 6 ~~alkynyl~~ alkynylene, by sulfone, by CO, by NR<sup>7</sup>CO, by CONR<sup>7</sup>, by NR<sup>7</sup>, by S, or by C(OH), or is fused to the next ring in the bicyclic, tricyclic, or tetracyclic ring structure;

R<sup>6</sup> and R<sup>7</sup> independently represent H or C1 to 6 alkyl;

and when the group  $\text{--NR}^5\text{Y--}$  represents an azacyclic ring and L represents a direct bond, the group  $\text{G}^1$  may also be spiro fused to the azacyclic ring;

2. (Original) A compound according to claim 1, wherein X represents  $\text{S(O)}_2$ .
3. (Previously presented) A compound according to claim 1, wherein  $\text{R}^1$  and  $\text{R}^2$  each represent hydrogen.
4. (Previously presented) A compound according claim 1, wherein  $\text{R}^3$  and  $\text{R}^4$  each represent hydrogen.
5. (Previously presented) A compound according to claim 1, wherein  $\text{R}^5$  represents hydrogen or C1 to 6 alkyl and Y represents a direct bond.
6. (Previously presented) A compound according to claim 1, wherein the group  $\text{--NR}^5\text{Y--}$  together represents a five or six membered saturated or partially unsaturated azacyclic ring, said azacyclic ring optionally incorporating one further heteroatom selected from O,  $\text{S(O)}_n$  and N.
7. (Currently Amended) A compound according to claim 1, wherein L represents a direct bond, O, ~~divalent C2 to 6 alkynyl~~ alkynylene, ~~divalent C1 to 6 alkyl~~ alkylene, ~~divalent C1 to 6 heteroalkyl~~ heteroalkylene or ~~divalent C3 to 6 heteroalkynyl~~ heteroalkynylene.
8. (Previously presented) A compound according to claim 1, wherein  $\text{G}^1$  represents an optionally substituted monocyclic or bicyclic ring structure.

9. (Currently Amended) A compound according to claim 1 which is selected from the group consisting of:

5-[(4-[(5-chloropyridin-2-yl)oxy]piperidin-1-yl)sulfonyl)methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-[2-(4-[(5-chloropyridin-2-yl)oxy]piperidin-1-yl)sulfonyl]ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-[3-(4-[(5-chloropyridin-2-yl)oxy]piperidin-1-yl)sulfonyl]propyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-([4-(4-chlorophenyl)piperazin-1-yl)sulfonyl)methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-([4-[(2-methoxypyrimidin-5-yl)ethynyl]-3,6-dihydropyridin-1(2H)-yl)sulfonyl)methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-([4-{2-(trifluoromethyl)pyrimidin-5-yl}ethynyl]-3,6-dihydropyridin-1(2H)-yl)sulfonyl)methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-([4-[(2-cyclopropylpyrimidin-5-yl)ethynyl]-3,6-dihydropyridin-1(2H)-yl)sulfonyl)methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-([4-(4-chlorophenyl)piperidin-1-yl)sulfonyl)methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;  
N-benzyl-1-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methanesulfonamide;

1-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-N-(2-phenylethyl)methanesulfonamide;

5-(2-{[4-(4-chlorophenyl)piperidin-1-yl)sulfonyl}ethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-(2-{[4-(4-chlorophenyl)piperazin-1-yl)sulfonyl}ethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;


5-(3-{[4-(4-chlorophenyl)piperidin-1-yl)sulfonyl}propyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;

and


5-(3-{[4-(4-chlorophenyl)piperazin-1-yl)sulfonyl}propyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;

or a ~~and~~ pharmaceutically acceptable salt ~~salts~~ thereof.

10. (Currently Amended) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof which comprises:  
reaction of a compound of formula (II)



wherein L<sup>1</sup> represents a leaving group, with a compound of formula (III)



wherein;

R<sup>1</sup> and R<sup>2</sup> independently represent H or C1 to 6 alkyl; said alkyl being optionally further substituted by an aryl ring or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said aromatic ring being optionally further substituted by halogen, CF<sub>3</sub>, C1 to 4 alkyl or C1 to 4 alkoxy;



Each  $R^3$  and each  $R^4$  independently represents H or C1 to 6 alkyl; said alkyl being optionally further substituted by OH, C1 to 4 alkoxy, C1 to 4 alkylthio, amino, N-alkylamino or N,N-dialkylamino;

or  $R^3$  and  $R^4$  are bonded together so as to form a 3 to 7 membered ring; said ring optionally incorporating one heteroatom selected from O,  $S(O)_q$  and N;

m represents an integer 1, 2 or 3;

X represents a group  $S(O)$ ,  $S(O)_2$  or  $C(=O)$ ;

$R^5$  represents H or C1 to 6 alkyl; said alkyl being optionally further substituted by halogen, OH or C1 to 6 alkoxy;

Y represents a direct bond;

or Y and  $R^5$  are bonded together such that the group  $-NR^5Y-$  together represents a 4 to 7 membered saturated or partially unsaturated azacyclic ring; said azacyclic ring optionally incorporating one further heteroatom selected from O,  $S(O)_n$  and N; said azacyclic ring being optionally benzo fused; said azacyclic ring being optionally substituted by C1 to 6 alkyl, C1 to 6 alkoxy or OH;

L represents a direct bond;

or L represents O,  $S(O)_p$ ,  $C(O)$ ,  $NR^6$ ,  $C(O)NR^6$ ,  $NR^6C(O)$ , ~~divalent C2 to 6 alkynyl~~ alkynylene, ~~divalent C2 to 6 alkenyl~~ alkenylene, ~~divalent C1 to 6 alkyl~~ alkylene, ~~divalent C1 to 6 heteroalkyl~~

heteroalkylene or ~~divalent~~ C3 to 6 ~~heteroalkynyl~~ heteroalkynylene; said ~~divalent-alkyl~~ alkylene, ~~divalent-alkenyl~~ alkenylene or ~~divalent-alkynyl~~ alkynylene group being optionally further substituted by halogen, OH or C1 to 6 alkoxy;

n, p and q independently represent an integer 0, 1 or 2;

G<sup>1</sup> is a monocyclic ring structure of up to 7 ring atoms, which is selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical; or

G<sup>1</sup> is a bicyclic ring structure, wherein each ring in the bicyclic ring structure is, independently, a ring of up to 7 ring atoms, wherein each ring in the bicyclic ring structure is, independently, selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; wherein each ring in the bicyclic ring structure is, independently, optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl,

C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical; or

G<sup>1</sup> is a tricyclic ring structure, wherein each ring in the tricyclic ring structure is, independently, a ring of up to 7 ring atoms, wherein each ring in the tricyclic ring structure is, independently, selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; wherein each ring in the tricyclic ring structure is, independently, optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical; or

G<sup>1</sup> is a tetracyclic ring structure, wherein each ring in the tetracyclic ring structure is, independently, a ring of up to 7 ring atoms, wherein each ring in the tetracyclic ring structure is, independently, selected from cycloalkyl; cycloalkenyl; heterocycloalkyl; unsaturated heterocycloalkyl; aryl; or an aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; wherein each ring in the tetracyclic ring structure is, independently, optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~ N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical;

and when G<sup>1</sup> is a bicyclic ring structure, a tricyclic ring structure, or a tetracyclic ring structure, each ring in the bicyclic, tricyclic, or tetracyclic ring structure is, independently, joined to the next ring in the bicyclic, tricyclic, or tetracyclic ring structure by a direct bond, by -O-, by ~~divalent~~ C1 to 6 ~~alkyl~~ alkylene, by ~~divalent~~ C1-6 ~~haloalkyl~~ haloalkylene, by ~~divalent~~ C1 to 6 ~~heteroalkyl~~ heteroalkylene, by ~~divalent~~ C2 to 6 ~~alkenyl~~ alkenylene, by ~~divalent~~ C2 to 6 ~~alkynyl~~ alkynylene, by sulfone, by CO, by NR<sup>7</sup>CO, by CONR<sup>7</sup>, by NR<sup>7</sup>, by S, or by C(OH), or is fused to the next ring in the bicyclic, tricyclic, or tetracyclic ring structure;

R<sup>6</sup> and R<sup>7</sup> independently represent H or C1 to 6 alkyl;

and when the group  $\text{-NR}^5\text{Y-}$  represents an azacyclic ring and L represents a direct bond, the group  $\text{G}^1$  may also be spiro fused to the azacyclic ring and optionally thereafter forming a pharmaceutically acceptable salt.

11. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. (Previously Presented) A process for the preparation of a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

Claims 13-17. (Cancelled)

18. (Currently Amended) A compound according to claim 1, wherein  $\text{G}^1$  is phenyl, which is optionally substituted by one or more substituents independently selected from halogen, hydroxy, CHO, C1 to 6 alkyl, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~alkylsulfonamino~~, C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, alkylaminosulfonyl, C2 to 6 alkanoyl, aminocarbonyl, N-alkylamino-carbonyl, ~~N,N-amino-carbonyl~~, N,N-dialkylamino-carbonyl; wherein any alkyl radical within any substituent may itself be optionally substituted with one or more groups selected from halogen, hydroxy, C1 to 6 alkoxy, halo-C1 to 6 alkoxy, amino, N-alkylamino, N,N-dialkylamino, ~~N-alkylsulfonamino~~, N-C2 to 6 alkanoylamino, cyano, nitro, ~~mercapto~~, alkylthio, alkylsulfonyl, N-alkylaminosulfonyl, CHO, C2 to 6 alkanoyl, aminocarbonyl, N-alkylaminocarbonyl, and N,N-dialkylaminocarbonyl; and wherein any alkyl radical is a C1 to 6 alkyl radical.

19. (Previously Presented) A compound according to claim 18, wherein X represents S(O)<sub>2</sub>.

20. (Previously Presented) A compound according to claim 18, wherein R<sup>1</sup> and R<sup>2</sup> each represent hydrogen.

21. (Previously Presented) A compound according claim 18, wherein R<sup>3</sup> and R<sup>4</sup> each represent hydrogen.

22. (Previously Presented) A compound according to claim 18, wherein R<sup>5</sup> represents hydrogen or C1 to 6 alkyl and Y represents a direct bond.

23. (Previously Presented) A compound according to claim 18, wherein the group –NR<sup>5</sup>Y– together represents a five or six membered saturated or partially unsaturated azacyclic ring, said azacyclic ring optionally incorporating one further heteroatom selected from O, S(O)<sub>n</sub> and N.

24. (Currently Amended) A compound according to claim 18 wherein L represents a direct bond, O, ~~divalent C2 to 6 alkynyl~~ alkynylene, ~~divalent C1 to 6 alkyl~~ alkylene, ~~divalent C1 to 6 heteroalkyl~~ heteroalkylene or ~~divalent C3 to 6 heteroalkynyl~~ heteroalkynylene.

25. (Previously Presented) A compound according to claim 18 which is selected from the group consisting of:

5-({[4-(4-chlorophenyl)piperazin-1-yl]sulfonyl}methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;

5-({[4-(4-chlorophenyl)piperidin-1-yl]sulfonyl}methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;

N-benzyl-1-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methanesulfonamide;

1-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-N-(2-phenylethyl)methanesulfonamide;

5-(2- {[4-(4-chlorophenyl)piperidin-1-yl]sulfonyl}ethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;  
5-(2- {[4-(4-chlorophenyl)piperazin-1-yl]sulfonyl}ethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;  
5-(3- {[4-(4-chlorophenyl)piperidin-1-yl]sulfonyl}propyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;  
and  
5-(3- {[4-(4-chlorophenyl)piperazin-1-yl]sulfonyl}propyl)-2,4-dihydro-3H-1,2,4-triazol-3-one;  
or a pharmaceutically acceptable salt thereof.

26. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 18 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

27. (Previously Presented) A process for the preparation of a pharmaceutical composition, which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 18 with a pharmaceutically acceptable adjuvant, diluent or carrier.

28. (Cancelled)